Project
afgesloten

Patient preferences in the choice of disease-modifying antirheumatic drugs (DMARDs)

Disease-modifying antirheumatic drugs (DMARDs) play a central role in the treatment of rheumatoid arthritis (RA). There is a wide variety of DMARDs available, and each DMARD has different attributes (e.g. administration route but also side effects). Incorporating patients’ preferences in treatment decisions is preferable. To date, little is known about the attributes and associated levels that are relevant to RA patients in the choice of DMARDs.

This study comprises a qualitative part to identify and select attributes and associated levels of DMARDs, and a quantitative part to elicit preferences of RA patients in the choice of DMARDs.

Several methods are used to identify and select attributes and attribute levels: a literature study, expert recommendations and focus groups. Hereafter, a discrete choice experiment is conducted to elicit preferences of RA patients in the choice of DMARDs.

Insight into patient preferences in the choice of disease-modifying antirheumatic drugs.
Funding
Pfizer
In this project we work together with
Sint Maartenskliniek (Bart van den Bemt)